Interestingly, TOX2 methylation among lung adenocarcinoma patients was significantly more prevalent in tumors from current smokers 43% (16/37) compared to never smokers 24% (18/75) or current non-smokers (former and never smokers combined) 26% (35/134) (p<0.05). This evidence concerns the gene TOX2 and lung adenocarcinoma.